Scientists thrilled after finding elusive 'tiny mystery' flower thriving in unexpected location: 'There's still hope'
According to LAist, this endangered flower, which at least one scientist has referred to as a "tiny mystery," was thought to only have a global population of around 10,000 until this discovery, leaving researchers stunned and excited.
Due to scientists' belief that the Camatta Canyon amole was limited in population, the plant is currently protected by federal and state Endangered Species Acts, though this may change with the recent discovery.
The plant is geographically concentrated, growing in only a couple of locations within a 90-acre area. Between the centralized growth area, grazing by livestock, and being run over by off-road vehicles, the plant has had a challenging time thriving.
As for why the amole has suddenly reappeared, scientists theorize that weather conditions may have strengthened underground amole bulbs. Drought-like conditions from previous years may have harmed plants competing with the amole for space and resources, while subsequent years saw higher amounts of rainfall, which could have reached the bulbs.
However, it is also possible that the plant was around the whole time, and no one came across it.
The discovery of so many of these flowers is a reason for optimism, as it could mean finding more blooms in the area. The U.S. Fish and Wildlife Service reviews animal and plant species considered threatened every five years, and scientists hope that by the next review, they will have found enough amoles to remove the plant from the endangered list.
Considering this amole has been in decline for decades, this finding opens up the possibility for research that could lead to a wealth of new knowledge about the flower.
The reemergence of the Camatta Canyon amole could help rebalance the local ecosystem, too, making it healthier and more diverse. Not only would that protect endangered species of all kinds, but it would also benefit human well-being by protecting food and water sources, as well as limiting the spread of disease.
Heather Schneider, a senior rare plant conservation scientist at the Santa Barbara Botanical Garden, told LAist, "All is not lost. There's still hope. Nature waits. And I hope it inspires people that putting efforts into conservation and looking for plants pays off."
Do you worry about having toxic forever chemicals in your home?
Majorly
Sometimes
Not really
I don't know enough about them
Click your choice to see results and speak your mind.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial
SAN DIEGO, July 08, 2025--(BUSINESS WIRE)--Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Through this collaboration, LabPMM (Invivoscribe's global reference laboratories) have customized their multiparametric flow cytometry (MFC) services and implemented their sensitive MFC AML MRD assay to support CERo's clinical trial of its lead compound, CER-1236. The trial targets Acute Myeloid Leukemia (AML) in patients who are relapsed/refractory, in remission with MRD, or newly diagnosed with TP53-mutated MDS/AML. AML is an aggressive blood cancer characterized by the rapid accumulation of abnormal myeloid cells in the bone marrow and blood, disrupting normal hematopoiesis.1 Treating AML is especially complex due to its genetic heterogeneity and the high risk of relapse. CAR-T (chimeric antigen receptor T-cells) and Chimeric Engulfment Receptor T-cells ("CER-T") therapies, which involve engineering a patient's own T-cells to recognize and attack cancer cells, have shown promise in other hematologic malignancies and are now being explored for AML. However, because these therapies are manufactured from patient-derived cells, it's critical to confirm that leukemic blasts are not inadvertently included in the final therapeutic product – underscoring the need for sensitive, validated assays like those offered by Invivoscribe and its global accredited regional laboratories, LabPMM. LabPMM's CAP/CLIA-Validated AML MRD MFC assay, which was designed to quantify residual leukemic cells in patients undergoing treatment, was customized to meet two critical needs in CERo's drug development program: (1) assessing the purity of the manufactured T-cell product by detecting residual AML blasts prior to infusion, and (2) evaluating therapeutic response to CER-1236 during the trial. Kristen Pierce, Ph.D., CERo Chief Development Officer, commented, "Invivoscribe has played an integral role in the execution of this clinical trial. Its technology and expertise have facilitated our advancement into the clinic by helping to ensure the purity of our investigational product, and now we are reaping the benefits of our collaboration as the trial is underway and we seek to assess therapeutic response." This collaborative effort was instrumental in advancing CER-1236, which recently received FDA Orphan Drug Designation for the treatment of AML2. The designation highlights the growing urgency of integrated diagnostic support in the advancement of personalized immunotherapies and reflects Invivoscribe's commitment to driving innovation and standardization across the oncology treatment landscape – now helping bring immunotherapies to patients faster. For more information about LabPMM's flow cytometry and molecular testing services, please visit or contact us at inquiry@ and follow us on LinkedIn. About Invivoscribe Inc. Invivoscribe® is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with pharmaceutical companies interested in clinical trial testing via our global lab network located in the U.S., Germany, Japan and China, and in developing and commercializing companion diagnostics, with our rigorous expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM®), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization. About CERo Therapeutics Holdings, Inc. CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ("CER-T"). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ("CAR-T") cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate CER-1236 for hematological malignancies. 1 2 View source version on Contacts inquiry@ Connectez-vous pour accéder à votre portefeuille

Yahoo
2 hours ago
- Yahoo
Boston's biotech sector reels due to Trump health policy uncertainty
The live music, free drinks and dancing at a big Boston biotech conference in June belied a stark reality: the city's biotech sector is in Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo
2 hours ago
- Yahoo
Meta's AI climate tool raised false hope of CO₂ removal, scientists say
Meta has been accused of using faulty data to train an artificial intelligence climate tool, with scientists claiming the Big Tech group